• 제목/요약/키워드: Ilsan, Korea

검색결과 381건 처리시간 0.038초

The Clinical Impact of β-Blocker Therapy on Patients With Chronic Coronary Artery Disease After Percutaneous Coronary Intervention

  • Jiesuck Park;Jung-Kyu Han;Jeehoon Kang;In-Ho Chae;Sung Yun Lee;Young Jin Choi;Jay Young Rhew;Seung-Woon Rha;Eun-Seok Shin;Seong-Ill Woo;Han Cheol Lee;Kook-Jin Chun;DooIl Kim;Jin-Ok Jeong;Jang-Whan Bae;Han-Mo Yang;Kyung Woo Park;Hyun-Jae Kang;Bon-Kwon Koo;Hyo-Soo Kim
    • Korean Circulation Journal
    • /
    • 제52권7호
    • /
    • pp.544-555
    • /
    • 2022
  • Background and Objectives: The outcome benefits of β-blockers in chronic coronary artery disease (CAD) have not been fully assessed. We evaluated the prognostic impact of β-blockers on patients with chronic CAD after percutaneous coronary intervention (PCI). Methods: A total of 3,075 patients with chronic CAD were included from the Grand Drug-Eluting Stent registry. We analyzed β-blocker prescriptions, including doses and types, in each patient at 3-month intervals from discharge. After propensity score matching, 1,170 pairs of patients (β-blockers vs. no β-blockers) were derived. Primary outcome was defined as a composite endpoint of all-cause death and myocardial infarction (MI). We further analyzed the outcome benefits of different doses (low-, medium-, and high-dose) and types (conventional or vasodilating) of β-blockers. Results: During a median (interquartile range) follow-up of 3.1 (3.0-3.1) years, 134 (5.7%) patients experienced primary outcome. Overall, β-blockers demonstrated no significant benefit in primary outcome (hazard ratio [HR], 0.88; 95% confidence interval [CI], 0.63-1.24), all-cause death (HR, 0.87; 95% CI, 0.60-1.25), and MI (HR, 1.25; 95% CI, 0.49-3.15). In subgroup analysis, β-blockers were associated with a lower risk of all-cause death in patients with previous MI and/or revascularization (HR, 0.38; 95% CI, 0.14-0.99) (p for interaction=0.045). No significant associations were found for the clinical outcomes with different doses and types of β-blockers. Conclusions: Overall, β-blocker therapy was not associated with better clinical outcomes in patients with chronic CAD undergoing PCI. Limited mortality benefit of β-blockers may exist for patients with previous MI and/or revascularization.

Clinical Characteristics of Chronic Cough in Korea

  • An, Tai Joon;Kim, Jin Woo;Choi, Eun Young;Jang, Seung Hun;Lee, Hwa Young;Kang, Hye Seon;Koo, Hyeon-Kyoung;Lee, Jong Min;Kim, Sung-Kyung;Shin, Jong-Wook;Park, So Young;Rhee, Chin Kook;Moon, Ji-Yong;Kim, Yee Hyung;Lee, Hyun;Kim, Yong Hyun;Kim, Je Hyeong;Lee, Sang Haak;Kim, Deog Kyeom;Yoo, Kwang Ha;Kim, Dong-Gyu;Jung, Ki-Suck;Kim, Hui Jung;Yoon, Hyoung Kyu;Cough Study Group of the Korean Academy of Tuberculosis and Respiratory Diseases
    • Tuberculosis and Respiratory Diseases
    • /
    • 제83권1호
    • /
    • pp.31-41
    • /
    • 2020
  • Background: Chronic cough is defined as a cough lasting more than 8 weeks and socio-economic burden of chronic cough is enormous. The characteristics of chronic cough in Korea are not well understood. The Korean Academy of Tuberculosis and Respiratory Diseases (KATRD) published guidelines on cough management in 2014. The current study evaluated the clinical characteristics of chronic cough in Korea and the efficacy of the KATRD guidelines. Methods: This was a multi-center, retrospective observational study conducted in Korea. The participants were over 18 years of age. They had coughs lasting more than 8 weeks. Subjects with current pulmonary diseases, smokers, exsmokers with more than 10 pack-years or who quit within the past 1 year, pregnant women, and users of cough-inducing medications were excluded. Evaluation and management of cough followed the KATRD cough-management guidelines. Results: Participants with chronic cough in Korea showed age in the late forties and cough duration of more than 1 year. Upper airway cough syndrome was the most common cause of cough, followed by cough-variant asthma (CVA). Gastro-esophageal reflux diseases and eosinophilic bronchitis were less frequently observed. Following the KATRD cough-management guidelines, 91.2% of the subjects improved after 4 weeks of treatment. Responders were younger, had a longer duration of cough, and an initial impression of CVA. In univariate and multivariate analyses, an initial impression of CVA was the only factor related to better treatment response. Conclusion: The causes of chronic cough in Korea differed from those reported in other countries. The current Korean guidelines proved efficient for treating Korean patients with chronic cough.

A Multicenter Study to Identify the Respiratory Pathogens Associated with Exacerbation of Chronic Obstructive Pulmonary Disease in Korea

  • Lee, Hyun Woo;Sim, Yun Su;Jung, Ji Ye;Seo, Hyewon;Park, Jeong-Woong;Min, Kyung Hoon;Lee, Jae Ha;Kim, Byung-Keun;Lee, Myung Goo;Oh, Yeon-Mok;Ra, Seung Won;Kim, Tae-Hyung;Hwang, Yong Il;Rhee, Chin Kook;Joo, Hyonsoo;Lee, Eung Gu;Lee, Jin Hwa;Park, Hye Yun;Kim, Woo Jin;Um, Soo-Jung;Choi, Joon Young;Lee, Chang-Hoon;An, Tai Joon;Park, Yeonhee;Yoon, Young-Soon;Park, Joo Hun;Yoo, Kwang Ha;Kim, Deog Kyeom
    • Tuberculosis and Respiratory Diseases
    • /
    • 제85권1호
    • /
    • pp.37-46
    • /
    • 2022
  • Background: Although respiratory tract infection is one of the most important factors triggering acute exacerbation of chronic obstructive pulmonary disease (AE-COPD), limited data are available to suggest an epidemiologic pattern of microbiology in South Korea. Methods: A multicenter observational study was conducted between January 2015 and December 2018 across 28 hospitals in South Korea. Adult patients with moderate-to-severe acute exacerbations of COPD were eligible to participate in the present study. The participants underwent all conventional tests to identify etiology of microbial pathogenesis. The primary outcome was the percentage of different microbiological pathogens causing AE-COPD. A comparative microbiological analysis of the patients with overlapping asthma-COPD (ACO) and pure COPD was performed. Results: We included 1,186 patients with AE-COPD. Patients with pure COPD constituted 87.9% and those with ACO accounted for 12.1%. Nearly half of the patients used an inhaled corticosteroid-containing regimen and one-fifth used systemic corticosteroids. Respiratory pathogens were found in 55.3% of all such patients. Bacteria and viruses were detected in 33% and 33.2%, respectively. Bacterial and viral coinfections were found in 10.9%. The most frequently detected bacteria were Pseudomonas aeruginosa (9.8%), and the most frequently detected virus was influenza A (10.4%). Multiple bacterial infections were more likely to appear in ACO than in pure COPD (8.3% vs. 3.6%, p=0.016). Conclusion: Distinct microbiological patterns were identified in patients with moderate-to-severe AE-COPD in South Korea. These findings may improve evidence-based management of patients with AE-COPD and represent the basis for further studies investigating infectious pathogens in patients with COPD.

Revised Korean Cough Guidelines, 2020: Recommendations and Summary Statements

  • Joo, Hyonsoo;Moon, Ji-Yong;An, Tai Joon;Choi, Hayoung;Park, So Young;Yoo, Hongseok;Kim, Chi Young;Jeong, Ina;Kim, Joo-Hee;Koo, Hyeon-Kyoung;Rhee, Chin Kook;Lee, Sei Won;Kim, Sung Kyoung;Min, Kyung Hoon;Kim, Yee Hyung;Jang, Seung Hun;Kim, Deog Kyeom;Shin, Jong Wook;Yoon, Hyoung Kyu;Kim, Dong-Gyu;Kim, Hui Jung;Kim, Jin Woo
    • Tuberculosis and Respiratory Diseases
    • /
    • 제84권4호
    • /
    • pp.263-273
    • /
    • 2021
  • Cough is the most common respiratory symptom that can have various causes. It is a major clinical problem that can reduce a patient's quality of life. Thus, clinical guidelines for the treatment of cough were established in 2014 by the cough guideline committee under the Korean Academy of Tuberculosis and Respiratory Diseases. From October 2018 to July 2020, cough guidelines were revised by members of the committee based on the first guidelines. The purpose of these guidelines is to help clinicians efficiently diagnose and treat patients with cough. This article highlights the recommendations and summary of the revised Korean cough guidelines. It includes a revised algorithm for the evaluation of acute, subacute, and chronic cough. For a chronic cough, upper airway cough syndrome (UACS), cough variant asthma (CVA), and gastroesophageal reflux disease (GERD) should be considered in differential diagnoses. If UACS is suspected, first-generation antihistamines and nasal decongestants can be used empirically. In cases with CVA, inhaled corticosteroids are recommended to improve cough. In patients with suspected chronic cough due to symptomatic GERD, proton pump inhibitors are recommended. Chronic bronchitis, bronchiectasis, bronchiolitis, lung cancer, aspiration, intake of angiotensin-converting enzyme inhibitor, intake of dipeptidyl peptidase-4 inhibitor, habitual cough, psychogenic cough, interstitial lung disease, environmental and occupational factors, tuberculosis, obstructive sleep apnea, peritoneal dialysis, and unexplained cough can also be considered as causes of a chronic cough. Chronic cough due to laryngeal dysfunction syndrome has been newly added to the guidelines.

Clinical Features, Diagnosis, Management, and Outcomes of Idiopathic Pulmonary Fibrosis in Korea: Analysis of the Korea IPF Cohort (KICO) Registry

  • Jegal, Yangjin;Park, Jong Sun;Kim, Song Yee;Yoo, Hongseok;Jeong, Sung Hwan;Song, Jin Woo;Lee, Jae Ha;Lee, Hong Lyeol;Choi, Sun Mi;Kim, Young Whan;Kim, Yong Hyun;Choi, Hye Sook;Lee, Jongmin;Uh, Soo-Taek;Kim, Tae-Hyung;Kim, Sang-Heon;Lee, Won-Yeon;Kim, Yee Hyung;Lee, Hyun-kyung;Lee, Eun Joo;Heo, Eun Young;Yang, Sei Hoon;Kang, Hyung Koo;Chung, Man Pyo;Korea ILD Study Group,
    • Tuberculosis and Respiratory Diseases
    • /
    • 제85권2호
    • /
    • pp.185-194
    • /
    • 2022
  • Background: The Korea Interstitial Lung Disease Study Group has made a new nationwide idiopathic pulmonary fibrosis (IPF) registry because the routine clinical practice has changed due to new guidelines and newly developed antifibrotic agents in the recent decade. The aim of this study was to describe recent clinical characteristics of Korean IPF patients. Methods: Both newly diagnosed and following IPF patients diagnosed after the previous registry in 2008 were enrolled. Survival analysis was only conducted for patients diagnosed with IPF after 2016 because antifibrotic agents started to be covered by medical insurance of Korea in October 2015. Results: A total of 2,139 patients were analyzed. Their mean age at diagnosis was 67.4±9.3 years. Of these patients, 76.1% were males, 71.0% were ever-smokers, 14.4% were asymptomatic at the time of diagnosis, and 56.9% were at gender-age-physiology stage I. Occupational toxic material exposure was reported in 534 patients. The mean forced vital capacity was 74.6% and the diffusing capacity for carbon monoxide was 63.6%. Treatment with pirfenidone was increased over time: 62.4% of IPF patients were treated with pirfenidone initially. And 79.2% of patients were treated with antifiboritics for more than three months during the course of the disease since 2016. Old age, acute exacerbation, treatment without antifibrotics, and exposure to wood and stone dust were associated with higher mortality. Conclusion: In the recent Korean IPF registry, the percentage of IPF patients treated with antifibrotics was increased compared to that in the previous IPF registry. Old age, acute exacerbation, treatment without antifibrotics, and exposure to wood and stone dust were associated with higher mortality.

진단방사선영역에서 방사선장치의 이용실태 및 환자피폭선량에 관한 조사연구 (A Study on the Utilization of Diagnostic Equipments and Patient Dose for Diagnostic Radiological Procedures in Korea)

  • 김유현;최종학;김성수;이창엽;조평곤;이영배;김철민
    • 한국의학물리학회지:의학물리
    • /
    • 제16권1호
    • /
    • pp.10-15
    • /
    • 2005
  • IAEA는 영상의 질에 영향을 주지 않는 범위에서 피부흡수선량의 기준선량을 제시하였다. 이러한 개념은 점차적으로 국제적인 기준으로 사용하게 되었다. 이 기준선량은 강제사항이 아니며 권고사항이지만 방사선촬영에서 아주 훌륭한 기준이 된다. 그러나 IAEA에서 제공한 선량기준은 서양 사람을 기준으로 개발된 것이어서 우리나라 사람에게는 맞지 않고, 상대적으로 우리나라의 환자선량은 적으리라 예상된다. 따라서 방사선촬영 시 촬영부위에 따른 환자 피폭선량에 대한 기준을 따로 개발해야 할 필요가 있다. 본 연구팀은 병원협회에 등록되어 있는 종합병원 278개를 대상으로 환자 피폭에 대한 설문조사를 실시하였다. 설문회수율은 57.9%였으며 각 병원에서 답한 촬영조건을 기초로 NDD법을 이용하여 환자 피폭선량을 계산하였고 방사선장치의 이용현황을 분석한 결과는 다음과 같다 1) 방사선장치의 현황은 일반촬영장치가 42.0%, 투시촬영장치가 29.4%, 치과장치가 13.2%, CT 장치가 8.1% 그리고 유방촬영장치가 7.2%로 나타났다. 2) 방사선장치의 정류방식에 따른 분류는 삼상장치가 29.9%, 인버터장치가 29.5%, 단상장치가 25.5%, 콘덴서방식이 9.0% 그리고 무응답이 6.0%였다. 3) 방사선장치의 수광방식에 따른 분류는 F/S 방식이 46.8%, CR 방식이 26.6%, DR 방식이 17.7% 그리고 무응답이 8.9%로 나타났다. 4) 방사선 촬영건수는 흉부가 49.2%, 척추가 16.8% 그리고 복부가 12.7%순으로 나타났다. 5) 환자 피폭선량은 두부 전후방향촬영 2.23 mGy, 복부 전후방향촬영 3.20 mGy 그리고 흉부 후전방향촬영 0.28 mGy로 나타났다.

  • PDF

2000-2001년 수도권 지역 홍역 유행의 양상 (The Characteristics of the 2000-2001 Measles Epidemic in the Seoul Metropolitan Area)

  • 피대훈;변소훈;김경범;유영;이기형;신영규
    • Clinical and Experimental Pediatrics
    • /
    • 제45권10호
    • /
    • pp.1219-1226
    • /
    • 2002
  • 목 적 : 국내에서는 1960년대 중반 이후 꾸준히 홍역 예방 접종을 시행해 옴에도 불구하고 2000-2001년에 전국적인 홍역의 대유행이 발생하였다. 저자들은 수도권 지역내 홍역 환아 중 입원 치료를 받은 환아를 대상으로 임상 양상의 특징을 조사하고 예방 접종의 효과에 대하여 알아보았다. 방 법: 2000년 6월부터 2001년 2월까지 고려대학교 안산병원, 관동대학교 일산 명지병원 및 서울 동부시립병원 소아과에서 임상적으로 진단된 홍역 환자 305명을 대상으로 연령과 성, 홍역 예방 접종력, 증상이 나타난 후 입원까지의 기간, 입원 기간, 합병증의 유무 및 그 유형 그리고 혈청 홍역 특이 IgM/IgG 항체를 검사하여 백신 실패율을 구하였다. 결 과 : 대상 환아 305명 중 12개월 미만은 118명(38.7%), 12-47개월은 84명(27.5%), 48개월 이상은 103명(33.8%)이었고 남녀비는 1.2 : 1로 남아가 많았다. 발병 연령은 $50.0{\pm}56.4$개월, 발진이 나타난 후 입원할 때까지의 기간은 $2.5{\pm}1.6$일, 재원 기간은 $6.4{\pm}3.4$일이었으며, 발진 발생 후 입원까지의 기간과 재원기간은 연령군 별로 유의한 차이를 보이지 않았다. 홍역 입원 환아는 2000년 6월부터 발생하기 시작하여 10월부터 현저히 증가되었으며 12월에 최고조에 달하였고 2001년 2월 이후로는 거의 발생하지 않았다. 유행은 연장아부터 시작되어 점차 어린 연령군으로 전파되는 양상을 보였다. 홍역 환아 중 1회 이상 홍역 예방 접종을 시행한 경우는 65.2%(199명)였고, 48개월 이상의 환아 중 현재의 예방 접종 권장안대로 2회 접종을 받은 경우는 13.6%였다. 1회의 홍역 예방 접종력이 있는 환아 180명 중 일차 백신 실패율은 59.4%(107/180명), 이차 백신 실패율은 3.9%(7/180명)였다. 61.6%의 환아가 합병증을 나타냈으며, 38.4%는 합병증이 나타나지 않았다. 합병증은 폐렴이 31.8%로 가장 많았고, 기관지염 11.5%, 중이염 4.6%의 순이었으며 백신 접종력 및 접종 횟수는 합병증의 발생과 유의한 상관성이 없었다. 결 론 : 2000년-2001년에 유행한 홍역의 임상 양상은 이전의 유행과 비교하여 볼 때 특이한 변화를 보이지는 않았으나 나이가 많은 연령층에서 시작하여 어린 연령층으로 확산되는 특징이 있었다. 홍역 환아들 중에서는 특히 일차 백신 실패율이 매우 높으므로 홍역 예방을 위해서는 이차 접종을 철저히 시행하는 것이 매우 중요하다.

Korean Children and Adolescents with Crohn's Disease Are More Likely to Present with Perianal Fistulizing Disease at Diagnosis Compared to Their European Counterparts

  • Kang, Ben;Kim, Jung Eun;Jung, Jae Hun;Choe, Jae Young;Kim, Mi Jin;Choe, Yon Ho;Kim, Seung;Koh, Hong;Lee, Yoo Min;Lee, Jee Hyun;Lee, Yoon;Lee, Ji-Hyuk;Lee, Hae Jeong;Jang, Hyo-Jeong;Choi, Youjin;Choi, So Yoon;Kim, Ju Young;Choe, Byung-Ho
    • Pediatric Gastroenterology, Hepatology & Nutrition
    • /
    • 제23권1호
    • /
    • pp.49-62
    • /
    • 2020
  • Purpose: We aimed to investigate the disease phenotype of Korean pediatric Crohn's disease (CD) patients at diagnosis according to the Paris classification by comparison with patients from the European multicenter 5-years recruitment of children with newly developed IBD (EUROKIDS registry). Methods: Korean children and adolescents who had been newly diagnosed with CD at the age of <18 years during 2013-2016 were included in this multicenter retrospective study. Disease phenotype at diagnosis was classified according to the Paris classification, and compared with the published data from the EUROKIDS study. Results: A total of 255 patients were included. The median diagnosis age was 14.7 years (range, 0.8-17.9 years). No significant difference was observed in male-to-female ratio with EUROKIDS (1.9:1 vs. 1.45:1, p=0.062). The proportion of children aged <10 years was significantly lower in Koreans (7.1% vs. 19.6%, p<0.001). Colonic disease was less prominent (10.0% vs. 27.3%, p<0.001), while upper GI involvement was more prominent in Korean children (59.3% vs. 46.2%, p<0.001). The proportion with perianal fistulizing disease at diagnosis was significantly higher in Korean patients (44.8% vs. 8.2%, p<0.001). A separate analysis of Korean patients revealed that perianal fistulizing disease at diagnosis was positively associated with male sex and body mass index z-score (odds ratio [OR]=2.12, 95% confidence interval [CI]=1.20-3.76, p=0.010; and OR=1.29, 95% CI=1.05-1.58, p=0.015, respectively). Conclusion: Approximately half of pediatric CD patients in Korea present with perianal fistulas and/or abscesses at diagnosis, which is a distinct feature of CD in Korean children and adolescents compared to their European counterparts. An underlying genetic difference between ethnicities may play a role in this expression of different phenotypes in pediatric CD.

Long-Term Survival Outcomes of Elderly Patients Treated With S-1 or Capecitabine Plus Oxaliplatin for Stage II or III Gastric Cancer: A Multicenter Cohort Study

  • Choi, Seohee;Min, Jae-Seok;Jeong, Sang-Ho;Yoo, Moon-Won;Son, Young-Gil;Oh, Sung Jin;Kim, Jong-Han;Park, Joong-Min;Hur, Hoon;Jee, Ye Seob;Hwang, Sun-Hwi;Jin, Sung-Ho;Lee, Sang Eok;Lee, Young-Joon;Seo, Kyung Won;Park, Sungsoo;Lee, Chang Min;Kim, Chang Hyun;Jeong, In Ho;Lee, Han Hong;Choi, Sung Il;Lee, Sang-Il;Kim, Chan-Young;Chae, Hyundong;Son, Myoung-Won;Pak, Kyung Ho;Kim, Sungsoo;Lee, Moon-Soo;Kim, Hyoung-Il
    • Journal of Gastric Cancer
    • /
    • 제22권1호
    • /
    • pp.67-77
    • /
    • 2022
  • Purpose: Tegafur/gimeracil/oteracil (S-1) and capecitabine plus oxaliplatin (CAPOX) are standard adjuvant chemotherapies (ACs) administered after gastrectomy to patients with stage II or III gastric cancer. However, the efficacy of AC in elderly patients remains unclear. The objective of this retrospective multicenter cohort study was to compare the efficacies of S-1 and CAPOX AC in patients aged ≥70 years. Materials and Methods: Nine hundred eighty-three patients who were treated with AC using S-1 (768 patients) or CAPOX (215 patients) were enrolled in this study. Each patient underwent AC after curative gastrectomy for stage II or III gastric cancer at one of 27 hospitals in the Republic of Korea between January 2012 and December 2013. Relapse-free survival (RFS) and overall survival (OS) were analyzed according to AC regimen and age group. Results: Of the 983 patients, 254 (25.8%) were elderly. This group had a similar RFS (P=0.099) but significantly poorer OS (p=0.003) compared with the non-elderly group. Subgroup analysis of the non-elderly group revealed no AC-associated differences in survival. Subgroup analysis of the elderly group revealed significantly better survival in the S-1 group than in the CAPOX group (RFS, P<0.001; OS, P<0.001). Multivariate analysis revealed that the CAPOX regimen was an independent poor prognostic factor for RFS (hazard ratio [HR], 1.891; 95% confidence interval [CI], 1.072-3.333; P=0.028) and OS (HR, 2.970; 95% CI, 1.550-5.692; P=0.001). Conclusions: This multicenter observational cohort study found significant differences in RFS and OS between S-1 and CAPOX AC among patients with gastric cancer aged ≥70 years.

코로나바이러스감염증-2019 유행 후 소아 장중첩증의 변화: 단일기관 10년 의무 기록을 이용한 연구 (The Effect of COVID-19 on Pediatric Intussusception: A Retrospective Study of a Single Center in South Korea with 10-Year Experience)

  • 유여진;제보경;최가영;이지현;최선규;이지영
    • 대한영상의학회지
    • /
    • 제83권2호
    • /
    • pp.304-316
    • /
    • 2022
  • 목적 코로나바이러스감염증-19 영향으로 소아청소년과 내원 환자 수가 현저히 감소한 2020년에 소아 장중첩증에는 어떤 변화가 발생했는지 알아보고자 한다. 대상과 방법 2011년부터 2020년까지 고려대학교 안산병원에 내원하여 장중첩증 진단 후 관장정복술을 받은 18세 미만의 환자의 성별, 나이, 관장정복술의 연도별/월별/계절별 빈도, 관장정복술의 연도별/월별 실패율, 장중첩증의 연도별/월별 재발률을 조사하였다. 또한 2011-2019년에 내원한 환자군과 2020년에 내원한 환자군 사이에 평균 나이, 관장정복술 실패율 및 장중첩증 재발률에서 통계적 차이가 있는지 분석하였다. 결과 10년간 859건의 관장정복술은 남아에서 더 많이 시행되었고 평균 나이는 22.2개월, 연령별로는 1세 미만이 가장 많았다. 연도별 빈도는 2014년에 가장 높았고 2020년에 가장 낮았으며, 월별 빈도는 12월과 9월이 높았고 3월이 가장 낮았다. 2020년 환자군(n = 27)은 2011-2019년 환자군(n = 832)에 비해 평균 나이가 어리고(18.1개월 vs. 22.8개월) 관장정복술 실패율이 높고 (7.4% vs. 2.4%) 장중첩증 재발률이 높았으나(14.8% vs. 7.3%) 통계적 유의성을 보이지는 않았다(p = 0.07, p = 0.15, p = 0.14). 결론 코로나바이러스감염증-19가 유행한 2020년에는 장중첩증으로 관장정복술을 받은 환자수가 급격히 감소하였고, 지난 10년의 기록과 비교할 때 환자의 나이가 더 어린 경향을 보였으며, 관장정복술의 실패율과 장중첩증 재발률은 가장 높은 수치를 기록하였다.